Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: A systematic review

Alexander Hann, Evelyn Nosalski, Patrick C. Hermann, Jan Egger, Thomas Seufferlein, Frieder Keller

Research output: Contribution to journalArticle

Abstract

Aims: New chemotherapeutic agents prolong survival of patients with pancreatic ductal adenocarcinoma (PDAC). Although their incidence is rising, patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) are not included in the phase III trials evaluating the effects of these chemotherapies. Many experts recommend applying chemotherapy after HD using a reduced dose. Alternatively, the concept of prior dosing allows for the application of dialyzable chemotherapeutic drugs using a normal dose, with an HD followed shortly after to mimic normal renal function. In this work, we provide guidance for clinicians on how to use chemotherapy in patients with PDAC on HD and how to identify substances suitable for prior dosing. Materials and methods: We systematically searched PubMed, from inception to September 2016, for published studies describing patients with ESRD on HD who received chemotherapies commonly applied in PDAC, including gemcitabine, fluorouracil (5-FU), capecitabine, oxaliplatin, irinotecan, docetaxel, erlotinib, sunitinib, S-1, and afatinib. Applied dosages, described toxicities, application time relative to HD, and pharmacokinetic measurements of the drug and its metabolites were assessed. Quantitative analysis of the drug plasma concentrations, including half-life during and in between HD and fraction of the drug eliminated during HD, were assessed. Results: We identified 56 studies describing 128 patients with ESRD undergoing HD during chemotherapeutic treatment. Quantitative pharmacokinetic analysis revealed that the following substances are dialyzable and thus suitable for application using the priordosing method: gemcitabine, 5-FU, oxaliplatin, irinotecan, and S-1. Conclusion: This work supports the application of dialyzable chemotherapeutic agents in patients with PDAC in standard dose when HD is performed shortly after the infusion.

LanguageEnglish
Pages125-141
Number of pages17
JournalClinical Nephrology
Volume90
Issue number2
DOIs
StatusPublished - 1 Aug 2018

Fingerprint

Pancreatic Neoplasms
Renal Dialysis
irinotecan
oxaliplatin
gemcitabine
Adenocarcinoma
Fluorouracil
Chronic Kidney Failure
Drug Therapy
docetaxel
Pharmaceutical Preparations
Pharmacokinetics
Proxy
PubMed
Half-Life
Kidney
Survival
Incidence

Keywords

  • Chemotherapy
  • Dialysis
  • End-stage renal disease
  • Pancreatic ductal adenocarcinoma
  • Pharmacokinetic

ASJC Scopus subject areas

  • Nephrology

Cite this

Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis : A systematic review. / Hann, Alexander; Nosalski, Evelyn; Hermann, Patrick C.; Egger, Jan; Seufferlein, Thomas; Keller, Frieder.

In: Clinical Nephrology, Vol. 90, No. 2, 01.08.2018, p. 125-141.

Research output: Contribution to journalArticle

Hann, Alexander ; Nosalski, Evelyn ; Hermann, Patrick C. ; Egger, Jan ; Seufferlein, Thomas ; Keller, Frieder. / Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis : A systematic review. In: Clinical Nephrology. 2018 ; Vol. 90, No. 2. pp. 125-141
@article{1bc39d324036405798e84f31288e661a,
title = "Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: A systematic review",
abstract = "Aims: New chemotherapeutic agents prolong survival of patients with pancreatic ductal adenocarcinoma (PDAC). Although their incidence is rising, patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) are not included in the phase III trials evaluating the effects of these chemotherapies. Many experts recommend applying chemotherapy after HD using a reduced dose. Alternatively, the concept of prior dosing allows for the application of dialyzable chemotherapeutic drugs using a normal dose, with an HD followed shortly after to mimic normal renal function. In this work, we provide guidance for clinicians on how to use chemotherapy in patients with PDAC on HD and how to identify substances suitable for prior dosing. Materials and methods: We systematically searched PubMed, from inception to September 2016, for published studies describing patients with ESRD on HD who received chemotherapies commonly applied in PDAC, including gemcitabine, fluorouracil (5-FU), capecitabine, oxaliplatin, irinotecan, docetaxel, erlotinib, sunitinib, S-1, and afatinib. Applied dosages, described toxicities, application time relative to HD, and pharmacokinetic measurements of the drug and its metabolites were assessed. Quantitative analysis of the drug plasma concentrations, including half-life during and in between HD and fraction of the drug eliminated during HD, were assessed. Results: We identified 56 studies describing 128 patients with ESRD undergoing HD during chemotherapeutic treatment. Quantitative pharmacokinetic analysis revealed that the following substances are dialyzable and thus suitable for application using the priordosing method: gemcitabine, 5-FU, oxaliplatin, irinotecan, and S-1. Conclusion: This work supports the application of dialyzable chemotherapeutic agents in patients with PDAC in standard dose when HD is performed shortly after the infusion.",
keywords = "Chemotherapy, Dialysis, End-stage renal disease, Pancreatic ductal adenocarcinoma, Pharmacokinetic",
author = "Alexander Hann and Evelyn Nosalski and Hermann, {Patrick C.} and Jan Egger and Thomas Seufferlein and Frieder Keller",
year = "2018",
month = "8",
day = "1",
doi = "10.5414/CN109327",
language = "English",
volume = "90",
pages = "125--141",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

TY - JOUR

T1 - Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis

T2 - Clinical Nephrology

AU - Hann,Alexander

AU - Nosalski,Evelyn

AU - Hermann,Patrick C.

AU - Egger,Jan

AU - Seufferlein,Thomas

AU - Keller,Frieder

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Aims: New chemotherapeutic agents prolong survival of patients with pancreatic ductal adenocarcinoma (PDAC). Although their incidence is rising, patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) are not included in the phase III trials evaluating the effects of these chemotherapies. Many experts recommend applying chemotherapy after HD using a reduced dose. Alternatively, the concept of prior dosing allows for the application of dialyzable chemotherapeutic drugs using a normal dose, with an HD followed shortly after to mimic normal renal function. In this work, we provide guidance for clinicians on how to use chemotherapy in patients with PDAC on HD and how to identify substances suitable for prior dosing. Materials and methods: We systematically searched PubMed, from inception to September 2016, for published studies describing patients with ESRD on HD who received chemotherapies commonly applied in PDAC, including gemcitabine, fluorouracil (5-FU), capecitabine, oxaliplatin, irinotecan, docetaxel, erlotinib, sunitinib, S-1, and afatinib. Applied dosages, described toxicities, application time relative to HD, and pharmacokinetic measurements of the drug and its metabolites were assessed. Quantitative analysis of the drug plasma concentrations, including half-life during and in between HD and fraction of the drug eliminated during HD, were assessed. Results: We identified 56 studies describing 128 patients with ESRD undergoing HD during chemotherapeutic treatment. Quantitative pharmacokinetic analysis revealed that the following substances are dialyzable and thus suitable for application using the priordosing method: gemcitabine, 5-FU, oxaliplatin, irinotecan, and S-1. Conclusion: This work supports the application of dialyzable chemotherapeutic agents in patients with PDAC in standard dose when HD is performed shortly after the infusion.

AB - Aims: New chemotherapeutic agents prolong survival of patients with pancreatic ductal adenocarcinoma (PDAC). Although their incidence is rising, patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) are not included in the phase III trials evaluating the effects of these chemotherapies. Many experts recommend applying chemotherapy after HD using a reduced dose. Alternatively, the concept of prior dosing allows for the application of dialyzable chemotherapeutic drugs using a normal dose, with an HD followed shortly after to mimic normal renal function. In this work, we provide guidance for clinicians on how to use chemotherapy in patients with PDAC on HD and how to identify substances suitable for prior dosing. Materials and methods: We systematically searched PubMed, from inception to September 2016, for published studies describing patients with ESRD on HD who received chemotherapies commonly applied in PDAC, including gemcitabine, fluorouracil (5-FU), capecitabine, oxaliplatin, irinotecan, docetaxel, erlotinib, sunitinib, S-1, and afatinib. Applied dosages, described toxicities, application time relative to HD, and pharmacokinetic measurements of the drug and its metabolites were assessed. Quantitative analysis of the drug plasma concentrations, including half-life during and in between HD and fraction of the drug eliminated during HD, were assessed. Results: We identified 56 studies describing 128 patients with ESRD undergoing HD during chemotherapeutic treatment. Quantitative pharmacokinetic analysis revealed that the following substances are dialyzable and thus suitable for application using the priordosing method: gemcitabine, 5-FU, oxaliplatin, irinotecan, and S-1. Conclusion: This work supports the application of dialyzable chemotherapeutic agents in patients with PDAC in standard dose when HD is performed shortly after the infusion.

KW - Chemotherapy

KW - Dialysis

KW - End-stage renal disease

KW - Pancreatic ductal adenocarcinoma

KW - Pharmacokinetic

UR - http://www.scopus.com/inward/record.url?scp=85049508067&partnerID=8YFLogxK

U2 - 10.5414/CN109327

DO - 10.5414/CN109327

M3 - Article

VL - 90

SP - 125

EP - 141

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 2

ER -